B
Bull
Bull · 25%IGMS
$1.69
情境價格
$1.270
-0.029 (-2.31%)收盤時
Loading chart…
- High
- 1.300
- Open
- 1.300
- VWAP
- 1.28
- Vol
- 1.62M
- Mkt Cap
- 390.15M
- Low
- 1.270
- Amount
- 2.07M
- EV/EBITDA, TTM
- 2.09
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
估值指標
The current forward P/E ratio for IGM Biosciences Inc (IGMS) is -1.45, compared to its 5-year average forward P/E of -3.40.
Alphio AI Price Scenarios for IGMS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
3.512-17BusinesswireiGMS Launches AI Features Reducing Guest Communication Time to 1.5 Hours
9.508-01NASDAQ.COMIGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
7.007-05GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, SPTN, IGMS on Behalf of Shareholders
8.507-02Globenewswire$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of IGM Biosciences, Inc. (NASDAQ: IGMS)
7.007-01PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, IGMS, SPTN, DNOW on Behalf of Shareholders
IGMS FAQ — answered by Alphio AI
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。